|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 05, 2012 ) Chicago, IL - Analysts at The Stockfather believe they have identified the next big stock in Tengion Inc. (Nasdaq:TNGN).
Tengion Inc. (TNGN) is a company that specializes in regenerative medicine. It is currently trading at .29 and has a float of 14 million shares.
Shares of TNGN could be trading much higher later this month. That's because the company is implementing a 1 for 10 reverse split. That move is needed to help the company maintain its listing on Nasdaq as well as to boost its stock value and structure.
Tengion (TNGN) is one of the hottest pharma stocks reports TheStockfather.com. It is developing products from a patient’s own cells that harness the body’s ability to regenerate native-like tissues and organs.
Tengion’s lead product is being developed for cancer patients who require removal of a cancerous bladder. The product is designed to eliminate the need to use the patient’s own bowel tissue in reconstruction of the urinary tract, thus potentially avoiding many complications.
If Tengion (TNGN) is acquired by another company, shares likely would fetch over $5 a share.
TheStockfather.com also predicted big gains for KERX and DNDN before they made giant runs up. KERX was trading at 18 cents when it was alerted and went on to hit $1.22. DNDN experienced a similar run so those are a couple good reasons to pay close attention to The Stockfather's picks.
About The Stockfather:
The Stockfather searches the market for undervalued penny and big board stocks.
Disclaimer:
The Stockfather was not paid to profile the company(ies) or stock(s) mentioned. The Stockfather does not own any shares of the stock(s) mentioned. The Stockfather is not a registered investment advisor. Investors are responsible for doing their own research and obtaining professional investment advice. Investors should visit http://www.thestockfather.com for further information.
The Stockfather
David Conway
312-473-5916
alerts@thestockfather.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
